Helicobacter pylori treatment: Still a work in progress

References

• Megraud F, Brassens-Rabbe MP, Denis F. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol. 1989;27:1870–1873.
   PubMed Web of Science ®Google Scholar
• Talebi Bezman AA. Helicobacter pylori: emergence of a superbug. Front Med (Lausanne). 2014;1:34.
   PubMedGoogle Scholar
• Malfertheiner P, Megraud F, O Morain C. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 consensus report. Aliment Pharmacol Ther. 2000;16:167–180.
   Web of Science ®Google Scholar
• Chey WD, Wong BC. Management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–1825.
   PubMed Web of Science ®Google Scholar
• Federico A, Gravina AG, Miranda A, et al. Eradication of Helicobacter pylori infection: which regimen first? World J Gastroenterol. 2014;20(3):665–672.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Kanemasa K, Imai S, et al. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. J Gastroenterol. 2015;50(9):996–1004.
   Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence consensus report. Gut. 2012;61(5):646–664.
   PubMed Web of Science ®Google Scholar
• Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter. 2010;15(1):38–45.
   PubMed Web of Science ®Google Scholar
• Choi HS, Chun HJ, Park SH, et al. Comparison of sequential and 7-,10-,14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol. 2012;18(19):2377–2382.
   PubMed Web of Science ®Google Scholar
• Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013;381(9862):205–213.
   PubMed Web of Science ®Google Scholar
• Yancey J, Neamand-Cheney K. Optimal duration of treatment regimens for H. pylori eradication. Am Fam Physician. 2014;90(11):766–767.
   PubMed Web of Science ®Google Scholar
• Furata T, Sugimoto M, Yamade M, et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol. 2014;54(3):258–266.
   PubMed Web of Science ®Google Scholar
• Xu MH, Zhang GY, Li CJ. Efficacy of bismuth-based quadruple therapy as first-line treatment for Helicobacter pylori infection. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2011;40(3):327–331.
   PubMedGoogle Scholar
• Liu KS, Hung IF, Seto WK, et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut. 2014;63(9):1410–1415.
   PubMed Web of Science ®Google Scholar
• Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56(10):1353–1357.
   PubMed Web of Science ®Google Scholar
• Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med. 2008;148(12):923–931.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Malfertheiner P. Editorial: sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol. 2009;104(12):3081–3083.
   PubMed Web of Science ®Google Scholar
• Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009;104(12):3069–3079.
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther. 2011;34(9):1098–1105.
   PubMed Web of Science ®Google Scholar
• Polat Z, Kadayifci A, Kantarcioglu M, et al. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori. Eur J Intern Med. 2012;23(2):165–168.
   PubMed Web of Science ®Google Scholar
• Zullo A, Ridola L, Efrati C, et al. First- and second-line Helicobacter pylori eradication with modified sequential therapy and modified levofloxacin-amoxicillin-based triple therapy. Ann Gastroenterol. 2014;27(4):357–361.
   PubMedGoogle Scholar
• Feng L, Wen MY, Zhu YJ, et al. Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systemic review. Am J Ther. 2015. doi:10.1097/MJT.0000000000000191. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Tsay FW, Wu DC, Kao SS, et al. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial. Helicobacter. 2015;20(1):71–77.
   PubMed Web of Science ®Google Scholar
• Cetinkaya ZA, Sezikli M, Güzelbulut F, et al. Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin. Helicobacter. 2010;15(2):143–147.
   PubMed Web of Science ®Google Scholar
• Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106(11):1970–1975.
   PubMed Web of Science ®Google Scholar
• Hsu PI, Wu DC, Chen WC, et al. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother. 2014;58(10):5936–5942.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kim JI, Lee JS, et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol. 2015; 7;21(1):351–359.
   PubMed Web of Science ®Google Scholar
• Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010;8(1):36–41.
   PubMed Web of Science ®Google Scholar
• Federico A, Nardone G, Gravina AG, et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology. 2012;143(1):55–61.
   PubMed Web of Science ®Google Scholar
• McNicholl AG, Marin AC, Molina-Infante J, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut. 2014;63(2):244–249.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 2014;20(30):10338–10347.
   PubMed Web of Science ®Google Scholar
• DeFrancesco V, Hassan C, Ridola L, et al. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol. 2014;63:748052.
   Google Scholar
• Gisbert JP, Bermejo F, Castro-Fernández M, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol. 2008;103(1):71–76.
   PubMed Web of Science ®Google Scholar
• Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010;59(11):1465–1470.
   PubMed Web of Science ®Google Scholar
• Assem M, El Azab G, Rasheed MA, et al. Efficacy and safety of levofloxacin, clarithromycin and esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. Eur J Intern Med. 2010;21(4):310–314.
   PubMed Web of Science ®Google Scholar
• Dib J Jr, Alvarez B, Mendez L, et al. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital. Arab J Gastroenterol. 2013;14(3):123–125.
   PubMedGoogle Scholar
• Rakici H, Ayaz T, Akdogan RA, et al. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. Digestion. 2014;90(4):261–264.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015;41(8):768–775.
   Web of Science ®Google Scholar
• Gisbert JP, Romano M, Molina-Infante J, et al. Two-week, high dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Dig Liver Dis. 2015;47(2):108–113.
   PubMedGoogle Scholar
• Sugimoto M, Sahara S, Ichikawa H, et al. High Helicobacter pylori cure rate with sitafloxacin-based triple therapy. Aliment Pharmacol Ther. 2015;42(4):477–483.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Castro-Fernandez M, Perez-Aisa A, et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther. 2012;35(8):941–947.
   PubMed Web of Science ®Google Scholar
• Miehlke S, Schneider-Brachert W, Kirsch C, et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2008;13(1):69–74.
   PubMed Web of Science ®Google Scholar
• Hajaghamohammadi A, Safiabadi Tali SH, Samimi R, et al. Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial. Glob J Health Sci. 2014;7(1):235–239.
   PubMedGoogle Scholar
• Cheng H, Fu-Lian H. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol. 2009;15(7):860–864.
   PubMed Web of Science ®Google Scholar
• Rogha M, Pourmoghaddas Z, Rezaee M, et al. Azithromycin effect on helicobacter pylori eradication: double blind randomized clinical trial. Hepatogastroenterology. 2009;56(91–92):722–724.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Ogasawara N, Utsumi K, et al. Changes in the 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitors. J Clin Biochem Nutr. 2010;47(1):53–58.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136:13–24.
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34–42.
   PubMed Web of Science ®Google Scholar
• Romano M, Marmo R, Cuomo A, et al. Pretreatment antimicrobial susceptibility testing is cost-saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol. 2003;1(4):273–278.
   PubMed Web of Science ®Google Scholar
• Dore MP, Marras L, Maragkoudakis E, et al. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter. 2003;8(4):307–309.
   PubMed Web of Science ®Google Scholar
• De Boer WA, Tytgat GNJ. Review: the best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol. 1995;30(5),401–407.
   PubMed Web of Science ®Google Scholar